Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Panel Testing for Familial Breast Cancer
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up
- The Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
- Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Triptorelin Plus Exemestane or Tamoxifen
- Changes in Expression of HER2 and Hormone Receptor Status After Neoadjuvant Chemotherapy
- Age at Primary Breast Cancer and Contralateral Cancer Risk in BRCA1/2 Carriers
- Cardiovascular Disease Risk in Breast Cancer Survivors
- Safety of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients
- SABCS 2015: Recommendations From Dr. Lee Schwartzberg
- Prediction of Response to Neoadjuvant Chemotherapy With the Prosigna Assay